Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Bastin

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 23, 2004
Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cellsFatima Djouadi, Flore Aubey, Dimitri Schlemmer, et al.
The New England Journal of Medicine|February 21, 2009
Bezafibrate for an inborn mitochondrial beta-oxidation defectJean-Paul Bonnefont, Jean Bastin, Anthony Behin, et al.
Molecular Genetics and Metabolism|March 6, 2003
Characterization of fatty acid oxidation in human muscle mitochondria and myoblastsFatima Djouadi, Jean Paul Bonnefont, Arnold Munnich, et al.
Journal of Inherited Metabolic Disease|October 15, 2014
Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?Jean Bastin, Jean-Paul Bonnefont, Fatima Djouadi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 24, 2008
Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its componentsJean Bastin, Flore Aubey, Agnès Rötig, et al.
Journal of Inherited Metabolic Disease|September 11, 2010
Current issues regarding treatment of mitochondrial fatty acid oxidation disordersUte Spiekerkoetter, Jean Bastin, Melanie Gillingham, et al.
International Journal of Molecular Sciences|April 19, 2019
Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum DisorderRita Barone, Renata Rizzo, Giovanni Tabbì, et al.
Molecules (Basel, Switzerland)|December 23, 2017
Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation DeficiencyVirginie Aires, Dominique Delmas, Fatima Djouadi, et al.
Cardiovascular Research|June 6, 2009
A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathyFatima Djouadi, Yves Lecarpentier, Jean-Louis Hébert, et al.
Biochimica Et Biophysica Acta|January 12, 2010
Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approachesStéphanie Gobin-Limballe, Ryan P McAndrew, Fatima Djouadi, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Endocrinology and Metabolism|December 23, 2004
Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cellsFatima Djouadi, Flore Aubey, Dimitri Schlemmer, et al.
The New England Journal of Medicine|February 21, 2009
Bezafibrate for an inborn mitochondrial beta-oxidation defectJean-Paul Bonnefont, Jean Bastin, Anthony Behin, et al.
Molecular Genetics and Metabolism|March 6, 2003
Characterization of fatty acid oxidation in human muscle mitochondria and myoblastsFatima Djouadi, Jean Paul Bonnefont, Arnold Munnich, et al.
Journal of Inherited Metabolic Disease|October 15, 2014
Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?Jean Bastin, Jean-Paul Bonnefont, Fatima Djouadi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 24, 2008
Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its componentsJean Bastin, Flore Aubey, Agnès Rötig, et al.
Journal of Inherited Metabolic Disease|September 11, 2010
Current issues regarding treatment of mitochondrial fatty acid oxidation disordersUte Spiekerkoetter, Jean Bastin, Melanie Gillingham, et al.
International Journal of Molecular Sciences|April 19, 2019
Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum DisorderRita Barone, Renata Rizzo, Giovanni Tabbì, et al.
Molecules (Basel, Switzerland)|December 23, 2017
Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation DeficiencyVirginie Aires, Dominique Delmas, Fatima Djouadi, et al.
Cardiovascular Research|June 6, 2009
A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathyFatima Djouadi, Yves Lecarpentier, Jean-Louis Hébert, et al.
Biochimica Et Biophysica Acta|January 12, 2010
Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approachesStéphanie Gobin-Limballe, Ryan P McAndrew, Fatima Djouadi, et al.
Pageof 5